HBIO - ハ―バ―ド・バイオサイエンス (Harvard Bioscience Inc.) ハ―バ―ド・バイオサイエンス



symbol HBIO
会社名 Harvard Bioscience Inc. (ハ―バ―ド・バイオサイエンス)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ハーバード・バイオサイエンス(Harvard Bioscience Inc.)は世界中の医薬品・バイオ医薬品会社、大学及び政府研究所の生命科学研究を推進するための専門製品、装置及び科学機器の開発・製造・販売に従事するグローバル企業である。同社は850ページのカタログ(及び各種専門カタログ)、ウェブサイト及びGE Healthcare、Thermo Fisher Scientific Inc.とVWR等の流通業者を通じて、100カ国以上の数千人の研究者に製品を販売する。同社の製品は毒性(ADMET)試験及び分子生物学の2つの応用分野をターゲットにする。平成24年2月1日、同社は完全所有子会社Biochrom Ltd.を通してAHN Biotechnologie GmbHの事業を買収した。平成23年7月、同社はCMA Microdialysis AB.の前臨床事業を買収した。   ハ―バ―ド・バイオサイエンスは、米国の医療機器製造会社。製薬会社、バイオテクノ ロジ―会社、大学、政府の実験室など向けに、医薬品研究開発用器具の設計、製造、販売を行う。同社のプロテオミクス関連器具は、たんぱく質および薬剤候補のテストに用いられるADMET (吸収-分布 -代謝-排泄 -毒性) 解析の精製や分析に用いられる。本社は、マサチュ―セッツ州ホリストン。   Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned academic institutions and government laboratories, to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, the company sells through a combination of direct and distribution channels to customers around the world.
本社所在地 84 October Hill Road Holliston MA 01746 USA
代表者氏名 James W. Green ジェームズ・W・グリーン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 508-893-8999
設立年月日 1901年
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 434人
url www.harvardbioscience.com
nasdaq_url https://www.nasdaq.com/symbol/hbio
EBITDA EBITDA(百万ドル) 4.39900
終値(lastsale) 4.61
時価総額(marketcap) 168631946.78
時価総額 時価総額(百万ドル) 156.92650
売上高 売上高(百万ドル) 110.79400
企業価値(EV) 企業価値(EV)(百万ドル) 212.75150
当期純利益 当期純利益(百万ドル) -4.24500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Harvard Bioscience Inc. revenues increased 57% to $58.3M. Net loss before extraordinary items increased from $1.4M to $7.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 73% to $11.7M (expense) Other expense net increase from $105K to $3.1M (expense).



   Harvard Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/16 19:39:15 Seeking Alpha
   Harvard Bioscience EPS misses by $0.10, beats on revenue  2021/08/05 11:16:36 Seeking Alpha
   Harvard Bioscience Announces Second Quarter 2021 Financial Results  2021/08/05 11:00:00 Intrado Digital Media
Strong double digit revenue growth, solid margin performance despite global supply chain disruptions
   Global Perfusion Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Getinge, Medtronic, LivaNova, Terumo Medical, Xenios, Lifeline Scientific, XVIVO Perfusion, Repligen Corporation, Spectrum Laboratories, Merck, Harvard Bioscience, Ala Science  2021/07/24 01:08:10 Jumbo News
The report on Global Perfusion Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition of []
   Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET  2021/07/19 20:45:00 Intrado Digital Media
HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
   The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs  2021/03/19 11:46:46 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) ENDRA Life Sciences Inc. (NASDAQ: NDRA ) (announced a collaboration with Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ) for NASH studies) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Neos Therapeutics, Inc. (NASDAQ: NEOS ) (reacted to the shareholder meeting held to vote on the proposal to merge with Aytu BioScience, Inc. (NASDAQ: AYTU )) NuVasive, Inc. (NASDAQ: NUVA ) SI-BONE, Inc. (NASDAQ: SIBN ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) Varian Medical Systems, Inc. (NASDAQ: VAR ) Vericel Corporation (NASDAQ: VCEL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 18) Foghorn Therapeutics Inc. (NASDAQ: FHTX ) (issued a corporate update) Galecto, Inc. (NASDAQ: GLTO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus Sarepta Presents Positive Data For Gene Therapy to Treat Limb-gridle Muscular Dystrophy Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) announced new results from the ongoing study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E, showing sustained protein expression in muscle tissue.
   The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq  2021/03/18 12:16:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 17) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) BioAtla, Inc. (NASDAQ: BCAB ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Immatics N.V. (NASDAQ: IMTX ) ( announced positive Phase 1 readout for a trio of candidates in solid tumors) NGM Biopharmaceuticals, Inc. (NASDAQ: NGM ) NuVasive, Inc. (NASDAQ: NUVA ) Omnicell, Inc. (NASDAQ: OMCL ) Oncternal Therapeutics, Inc. (NASDAQ: ONCT ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) PLx Pharma Inc. (NASDAQ: PLXP ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) STRATA Skin Sciences, Inc. (NASDAQ: SSKN ) Urovant Sciences Ltd. (NASDAQ: UROV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 17) Foghorn Therapeutics Inc. (NASDAQ: FHTX ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Stocks In Focus Translate Bio mRNA Product Candidate For Cystic Fibrosis Fails To Improve Lung Function In Phase 1/2 Study Translate Bio (NASDAQ: TBIO ) announced a second interim analysis from the Phase 1/2 study of MRT5005 in patients with cystic fibrosis, showing that repeat dosing was generally safe and well tolerated, with no serious adverse events.
   The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes  2021/03/17 11:43:07 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 16) Affimed N.V. (NASDAQ: AFMD ) BioAtla, Inc. (NASDAQ: BCAB ) Champions Oncology, Inc. (NASDAQ: CSBR ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Omnicell, Inc. (NASDAQ: OMCL ) Savara Inc. (NASDAQ: SVRA ) (reacted to a positive analyst action and insider buying) Sierra Oncology, Inc. (NASDAQ: SRRA ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 16) Galecto, Inc. (NASDAQ: GLTO ) Immunocore Holdings plc (NASDAQ: IMCR ) Stocks In Focus Pfizer to Sell Chinese Biologics Unit to WuXi Pfizer Inc.'s (NYSE: PFE ) China unit and Hong Kong-listed WuXi Biologics announced an equity agreement under which the latter will acquire the former's state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
   The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs  2021/03/12 12:36:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 11) Affimed N.V. (NASDAQ: AFMD ) AngioDynamics, Inc. (NASDAQ: ANGO ) Apyx Medical Corporation (NASDAQ: APYX ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) BioAtla, Inc. (NASDAQ: BCAB ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Entera Bio Ltd. (NASDAQ: ENTX ) ( announced positive Phase 2 biomarker data for osteoarthritis drug) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Inari Medical, Inc. (NASDAQ: NARI ) Jounce Therapeutics, Inc. (NASDAQ: JNCE ) Longeveron Inc. (NASDAQ: LGVN ) (announced FDA granting expanded access approval for its investigational cell therapy Lomecel-B to a pediatric patient with hypoplastic left heart syndrome) Magenta Therapeutics, Inc. (NASDAQ: MGTA ) Nuvation Bio Inc. (NASDAQ: NUVB )(announced orphan drug designation for NUV-422 in treating malignant gliomas) Renalytix AI plc (NASDAQ: RNLX ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Surmodics, Inc. (NASDAQ: SRDX ) Verrica Pharmaceuticals Inc. (NASDAQ: VRCA ) Down In The Dumps None of the NYSE- and Nasdaq-listed biotech/diagnostic shares hit 52-week lows Thursday.
   Harvard Bioscience Earnings Scorecard & Analyst Reports for Stock market Insights & financial analysis  2021/02/23 22:46:00 Stock Market Daily
Harvard Bioscience announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (先端医療機器_テクノロジ― 米国株 ハ―バ―ド・バイオサイエンス HBIO Harvard Bioscience Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)